Campbell et al., Totipotency or multipotentiality of cultured cells: Applications and progress, 1997, Theriogenology, vol. 47, pp. 63-72.* |
Sigmund, Viewpoint: Are studies in genetically altered mice out of control?, 2000, Arterioscler Thromb. Vasc. Biol., vol. 20, pp. 1425-1429.* |
Wall, Transgenic livestock: Progress and prospects for the future, 1996, Theriogenology, vol. 45, pp. 57-68.* |
Weinberg et al., Cloning and expression of a novel neuropeptide Y receptor, 1996, The Journal of Biological Chemistry, vol. 271, pp. 16435-16438.* |
Mansour et al., Disruption of the proto-oncogene int-2 in mouse embyro-derived stem cells: a general strategy for targeting mutations to non-selectable genes, 1988, Nature, vol. 336, pp. 348-352.* |
Bradley et al., Modifying the mouse: Design and desire, 1992, Bio/Technology, vol. 10, pp. 534-539.* |
Mullins et al., Perspective Series: Molecular medicine in genetically engineered animals, 1996, J. Clin. Invest., vol. 97, pp. 1557-1559.* |
Broqua, P. et al., Brain Res., 724:25-32 (1966), “Antinociceptive effects of neuropeptide Y and . . . ”. |
Castan, I. et al., Am. J. Physiol., 28(1):E74-E80 (1993), “Distribution of PYY receptors in human . . . ”. |
Clark, J. T. et al., Endocrinol., 115(1):427-429 (1984), “Neuropeptide Y and Human Pancreatic . . . ”. |
Clarke, J. G. et al., Lancet, 1(8541):1057-1059 (1987), “Coronary Artery Infusion of Neuropeptide . . . ”. |
Greber, S. et al., Br. J. Pharmacol., 113:737-740 (1994), “Neuropeptide Y inhibits potassium-. . . ”. |
Grundemar, L. et al., Gen. Pharmac., 24(4):785-796 (1993), “Multiple NeuropeptideY Receptors . . . ”. |
Hauser, G. J. et al., Am. J. Physiol., 34(4):H1416-H1423 (1993), “Neuropeptide Y infusion improves . . . ”. |
Urban, J. H. et al., Endocrinol., 132(1):139-145 (1993), “Neuropeptide Y Gene Expression in . . . ”. |
Wahlestedt, C. et al., Ann. NY Acad. Sci., 611:7-26 (1990), “Neuropeptide Y Receptor Subtypes . . . ”. |
Wahlestedt, C. et al., Annu. Rev. Pharmacol. Toxicol., 32:309-352 (1993), “Neuropeptide Y-Related . . . ”. |
Watanobe, H. et al., Biochem. and Biophys. Res. Comm., 200(2):1111-1117 (1994), “Neuropeptide . . . ”. |
Weinberg, D. H. et al., J. Biol. Chem., 271(28):16435-16438 (1996), “Cloning and Expression of a . . . ”. |
Zukowska-Grojec, Z. et al., Peptides; 14:263-268 (1993), “Mitogenic Effect of Neuropeptides Y in . . . ”. |
Heilig, M. et al., Psychopharmacol., 98:524-529 (1989), “Centrally administered neuropeptide Y . . . ”. |
Jorgensen, J. Ch. et al., Neuropeptides, 30(3):293-301 (1996), “Neuropeptide Y in the human . . . ”. |
Kalra, S. P. et al., Ann. NY Acad. Sci., 611:273-283 (1990), “Hypothalamic Neuropeptide Y . . . ”. |
Lacroix., J. S. et al., Br. J. Pharmacoal., 118-2079-2084 (1996), “Intranasal administration of . . . ”. |
Levine, A. S. et al., Peptides, 5:1025-1029 (1984), “Neuropeptide Y: a Potent Inducer of . . . ”. |
McDermott, B. J. et al., Cardiovasc. Res., 27:893-905 (1993), “Cardiovascular effects of neuro-. . . ”. |
Merten, M. D. et al., Am. J. Physiol., 10(5):L513-L-518 (1994), “Neuropeptide Y and norepinephrine . . . ”. |
Nakajima, M. et al., J. Pharmacol. Exp. Ther., 268(2):1010-1014 (1994), “Effects of Pancreatic . . . ”. |
Opara, E. C. et al., Reg. Peptides, 34:225-233 (1991), “Pancreatic hormone response to neuro-. . . ”. |
Oshita, M. et al., Gen. Pharmac., 20(3):363-367 (1989), “Selective Potentiation of Extracellular . . . ”. |
Sahu, A. et al., Endocrinol., 130(6):3331-3336 (1992), “Steroidal Regulation of Hypothalamic . . . ”. |
Skoglund, G. et al., Diabetes, 40:660-665 (1991), “Comparison of Effects of Neuropeptide Y . . . ”. |
Stanley, B. G. et al., Life Sci., 35:2635-2642 (1984), “Neuropeptide Y: Stimulation of Feeding . . . ”. |
Stephens, T. W. et al., Nature, 377(12):530-532 (1995), “The role of neuropeptide Y in the anti-. . . ”. |